scout

Joanna M. Rhodes, MD, MSCE
Joanna M. Rhodes, MD, MSCE

Joanna M. Rhodes, MD, MSCE, is director of Lymphoma and systems head for Lymphoma at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health

Articles by Joanna M. Rhodes, MD, MSCE

Experts on DLBCL

Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care

ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center

Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.

Expert on DLBCL

Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting

ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, The University of Texas MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center

Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.

Experts on DLBCL

Bridging Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center

Before closing out their discussion on the relapsed/refractory setting of diffuse large B-cell lymphoma, panelists identify best practices in bridging therapy.

Experts on DLBCL

Sequencing Novel Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center

Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.

Experts on DLBCL

Relapsed/Refractory DLBCL: Managing Patients on CAR T-Cell Therapy

ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center

A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.

Experts on DLBCL

Factors That Inform Sequencing of Therapy in Relapsed/Refractory DLBCL

ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center

Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Experts on DLBCL

Real-World Use of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center

Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Experts on DLBCL

CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Lisocabtagene Maraleucel

ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center

A brief review of data behind lisocabtagene maraleucel and its role as CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Experts on DLBCL

CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Axicabtagene Ciloleucel

ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center

Shared insight on the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, with a focus on axicabtagene ciloleucel.

Experts on DLBCL

Factors in Selecting Treatment for Relapsed/Refractory DLBCL

ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center

Focused discussion on specific patient or disease factors that aid in the selection of therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Experts on DLBCL

Diagnosis and Frontline Management of Diffuse Large B-Cell Lymphoma

ByJoanna M. Rhodes, MD, MSCE,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Yucai Wang, MD, PhD, Mayo Clinic,Hayder M. Saeed, MD, Moffitt Cancer Center

Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.